The information contained in these regimens is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment.
Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment.
The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient's preference.
Each treatment regimen has advantages and disadvantages, and there may be more than one good option. Also, treatment choices can change over time as more evidence becomes available.
Use of these documents is the responsibility of the prescribing clinician and is subject to the HSE.ie terms of use.
Please email any comments or feedback on these regimens to oncologydrugs@cancercontrol.ie
NTRK Gene Fusion Positive Solid Tumours
NCCP NTRK Gene Fusion Testing Guidance available here
| Regimen Name |
Indication |
|
Entrectninib Monotherapy - adult
Regimen
|
00702b
For the treatment of adult patients with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion,
- who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity and,
- who have not received a prior NTRK inhibitor
- who have no satisfactory treatment options
|
|
Larotrectinib Monotherapy - Adult
Regimen
|
00758a
For the treatment of adult patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,
- who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
- who have no satisfactory treatment options
|
|
Larotrectinib Monotherapy - Paediatric
Regimen
|
P00760a
For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,
- who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
- who have no satisfactory treatment options
|
| |
|
